SG10201914047RA - Novel endos mutant enzyme - Google Patents

Novel endos mutant enzyme

Info

Publication number
SG10201914047RA
SG10201914047RA SG10201914047RA SG10201914047RA SG10201914047RA SG 10201914047R A SG10201914047R A SG 10201914047RA SG 10201914047R A SG10201914047R A SG 10201914047RA SG 10201914047R A SG10201914047R A SG 10201914047RA SG 10201914047R A SG10201914047R A SG 10201914047RA
Authority
SG
Singapore
Prior art keywords
novel
mutant enzyme
endos mutant
endos
enzyme
Prior art date
Application number
SG10201914047RA
Inventor
Yoshirou KAWAGUCHI
Kensuke Nakamura
Yukiko Sekiguchi
Mitsuhiro Iwamoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG10201914047RA publication Critical patent/SG10201914047RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914047RA 2015-07-16 2016-07-15 Novel endos mutant enzyme SG10201914047RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015141901 2015-07-16

Publications (1)

Publication Number Publication Date
SG10201914047RA true SG10201914047RA (en) 2020-03-30

Family

ID=57757160

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914047RA SG10201914047RA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme
SG11201800394WA SG11201800394WA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201800394WA SG11201800394WA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme

Country Status (11)

Country Link
US (1) US11001819B2 (en)
EP (1) EP3323886B1 (en)
JP (1) JP6752203B2 (en)
KR (1) KR102546854B1 (en)
CN (1) CN108026518B (en)
AU (1) AU2016294206B9 (en)
ES (1) ES2848861T3 (en)
HK (1) HK1248271A1 (en)
SG (2) SG10201914047RA (en)
TW (1) TWI730972B (en)
WO (1) WO2017010559A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532990A (en) 2015-09-04 2018-11-08 オービーアイ ファーマ,インコーポレイテッド Glycan arrays and methods of use
CN109311995A (en) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 Antibody, pharmaceutical composition and method
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018071683A2 (en) 2016-04-22 2019-02-19 Obi Pharma, Inc. method for treating breast cancer, method for treating a tumor in a patient, method for treating an individual suffering from cancer by immunotherapy, method for inducing / improving an immune response in an individual, method for improving obi-822 induced vaccine by immune response in an individual in need thereof, method for identifying a patient suitable for cancer therapy, and method for determining a patient's cancer treatment prognosis or drug response
KR102493562B1 (en) * 2016-07-01 2023-01-30 다이이찌 산쿄 가부시키가이샤 Molecular conjugates containing hANP-Fc
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CN110036109A (en) * 2016-12-02 2019-07-19 第一三共株式会社 - β-N- acetylglucosaminidase in novel
TWI820044B (en) 2017-09-29 2023-11-01 日商第一三共股份有限公司 Antibody-pyrrolobenzodiazepine derivative complex
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
JPWO2020196474A1 (en) 2019-03-25 2020-10-01
EP3949987A4 (en) 2019-03-25 2023-02-22 Daiichi Sankyo Company, Limited Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
KR20220025721A (en) * 2019-08-05 2022-03-03 초 파마 인크. Fusion proteins for remodeling antibody glycoforms
AU2020420236A1 (en) 2020-01-10 2022-09-01 Fushimi Pharmaceutical Co., Ltd. Population of antibodies comprising homogeneous antibodies each having left-right asymmetric sugar chains, and method for producing same
EP4169934A1 (en) * 2020-06-18 2023-04-26 Shanghai Bao Pharmaceuticals Co., Ltd. Mutant of immunoglobulin degrading enzyme idee
EP4209506A1 (en) 2020-09-02 2023-07-12 Daiichi Sankyo Company, Limited Novel endo-?-n-acetylglucosaminidase
JPWO2022211075A1 (en) * 2021-03-31 2022-10-06

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190984B1 (en) * 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
JP5795067B2 (en) * 2011-07-21 2015-10-14 京セラ株式会社 Illumination device, image sensor head, and reader having the same
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
IN2014DN06806A (en) 2012-02-10 2015-05-22 Univ Maryland

Also Published As

Publication number Publication date
KR102546854B1 (en) 2023-06-22
JPWO2017010559A1 (en) 2018-04-26
CN108026518A (en) 2018-05-11
KR20180030536A (en) 2018-03-23
EP3323886A4 (en) 2019-02-27
AU2016294206A1 (en) 2018-02-08
EP3323886B1 (en) 2020-10-21
US20180208915A1 (en) 2018-07-26
WO2017010559A1 (en) 2017-01-19
AU2016294206B2 (en) 2021-12-02
ES2848861T3 (en) 2021-08-12
TWI730972B (en) 2021-06-21
CN108026518B (en) 2022-09-06
AU2016294206B9 (en) 2021-12-23
TW201708540A (en) 2017-03-01
SG11201800394WA (en) 2018-02-27
US11001819B2 (en) 2021-05-11
HK1248271A1 (en) 2018-10-12
JP6752203B2 (en) 2020-09-09
EP3323886A1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
HK1248271A1 (en) Novel endos mutant enzyme
EP3133960A4 (en) Improved mattress
EP3172993A4 (en) Pillow
EP3297586A4 (en) Oral appliance
EP3222714A4 (en) Phytase mutants
EP3310314A4 (en) Lift-assist chair
EP3270738A4 (en) Mattress
EP3438253A4 (en) Phytase mutant
EP3374718A4 (en) Coldwave appliance
EP3037812C0 (en) Enzyme electrode
LT3256486T (en) Griffithsin mutants
EP3354988A4 (en) Cooker
EP3346188A4 (en) Cooker
EP3399007A4 (en) Gasification furnace
EP3343110A4 (en) Cooker
EP3318167A4 (en) Cleaner
EP3099199A4 (en) Self-adjusting bed
EP3360427A4 (en) Cooked-rice improver having flavor improving action
EP3114968A4 (en) Height-adjustable pillow
ZA201608406B (en) Enzyme treatment composition
EP3322324A4 (en) Cleaning pad
EP3285546A4 (en) Cooker
EP3362755B8 (en) Furnace
EP3185823A4 (en) Oral appliance
EP3128004A4 (en) Enzyme agent